Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 7/20 | 0.83 |
| ▸ | POLA1 | P09884 | 2/20 | 0.83 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6708302 | 0.93 | KCNH2 (0.81) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6707899 | 0.92 | KCNH2 (0.81) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6706716 | 0.91 | POLA1 (1.00) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL30419552 | 0.91 | KCNH2 (1.00) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6666985 | 0.91 | KCNH2 (1.00) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6669876 | 0.90 | KCNH2 (0.89) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6706361 | 0.89 | POLA1 (0.94) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6672185 | 0.89 | KCNH2 (0.91) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6706433 | 0.89 | KCNH2 (0.87) | KCNH2POLA1MEN1KMT2AF2 | |
| SCHEMBL6706701 | 0.89 | POLA1 (0.93) | KCNH2POLA1MEN1KMT2AF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004019939-A1 | METHOD OF PREVENTING OR TREATING ATHEROSCLEROSIS OR RESTENOSIS | PHARMACIA & UPJOHN COMPANY (US) | 2004-03-11 | — | — | WO | claimed |